Compare Nasdaq100 ETF (QQQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs Recursion Pharmaceuticals Inc — how do they compare? Nasdaq100 ETF trades at $751.06 (market cap $506.92B), while Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B). The key difference: Nasdaq100 ETF is far larger — about 236.9× Recursion Pharmaceuticals Inc's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| QQQ | RXRX | |
|---|---|---|
Market Cap | $506.92B | $2.14B |
Volume | 48,326,518 | 30,789,535 |
52-Week High | $759.66 | $6.79 |
52-Week Low | $558.34 | $2.84 |
Typical Hold Time | 162 Days | 22 Days |
Sector | — | Health |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $757.73, down 0.25% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF shows mixed analyst sentiment with a 50% buy and 50% sell consensus. Recent news highlights comparisons with lower-fee alternatives like QQQM and VOO, while broader market concerns about AI valuations and interest rate impacts create headwinds.
The outlook for QQQ remains tied to technology sector performance and AI-driven growth, though elevated valuations and concentration risk warrant caution. Near-term support lies at $754, with resistance at $760. Investors face balancing growth potential against fee differentials and market volatility risks.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
